As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Lakefront Biotherapeutics NV. The largest reported stake is EcoR1 Capital, LLC's, at 13.22%. 3 filings are on record since July 28, 2025 (Schedule 13D/A, July 28, 2025).
Sell to companies like Lakefront Biotherapeutics NV? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Madison Avenue International LP · Sole voting: 0 · Shared voting: 3,606,203 · Sole dispositive: 0 · Shared dispositive: 3,606,203 · SCHEDULE 13G, 2026-06-23
- · Reporting person: Tang Capital Management, LLC · Sole voting: 0 · Shared voting: 5,559,674 · Sole dispositive: 0 · Shared dispositive: 5,559,674 · SCHEDULE 13G, 2025-10-29
- · Reporting person: EcoR1 Capital, LLC · Sole voting: 0 · Shared voting: 8,714,522 · Sole dispositive: 0 · Shared dispositive: 8,714,522 · SCHEDULE 13D/A, 2025-07-28
Lakefront Biotherapeutics NV has 3 Schedule 13D or 13G filings on record since 2025-07-28. 3 holders' latest filing reports 5% or more of ordinary shares, no nominal value per share (the "ordinary shares"). Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 13.22% | 8,714,522 | SCHEDULE 13D/A, 2025-07-28 | 2025-07-24 |
| Tang Capital Management, LLC | 8.4% | 5,559,674 | SCHEDULE 13G, 2025-10-29 | 2025-10-27 |
| Madison Avenue International LP | 5.5% | 3,606,203 | SCHEDULE 13G, 2026-06-23 | 2026-06-15 |
Holding shares or following this stake? See who's behind Lakefront Biotherapeutics NV and the warning signs.
Free to see. No signup.
Keep reading
More on Lakefront Biotherapeutics NV and the records around it.
Companies that share a holder
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), STAAR SURGICAL CO (Aug 2026)
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Lakefront Biotherapeutics NV
Get an email when Lakefront Biotherapeutics NV files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Lakefront Biotherapeutics NV?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lakefront Biotherapeutics NV: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lakefront Biotherapeutics NV covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 0 | 8,714,522 | 0 | 8,714,522 | SCHEDULE 13D/A, 2025-07-28 |
| Oleg Nodelman | 0 | 8,714,522 | 0 | 8,714,522 | SCHEDULE 13D/A, 2025-07-28 |
| EcoR1 Capital Fund Qualified, L.P. | 0 | 8,192,077 | 0 | 8,192,077 | SCHEDULE 13D/A, 2025-07-28 |
| EcoR1 Capital Fund, L.P. | 0 | 522,445 | 0 | 522,445 | SCHEDULE 13D/A, 2025-07-28 |
| Tang Capital Management, LLC | 0 | 5,559,674 | 0 | 5,559,674 | SCHEDULE 13G, 2025-10-29 |
| Kevin Tang | 0 | 5,559,674 | 0 | 5,559,674 | SCHEDULE 13G, 2025-10-29 |
| Tang Capital Partners, LP | 0 | 3,313,189 | 0 | 3,313,189 | SCHEDULE 13G, 2025-10-29 |
| Tang Capital Partners International, LP | 0 | 2,246,485 | 0 | 2,246,485 | SCHEDULE 13G, 2025-10-29 |
| Tang Capital Partners Iii, Inc | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2025-10-29 |
| Tang Capital Partners Iv, Inc | 0 | 0 | 0 | 0 | SCHEDULE 13G, 2025-10-29 |
| Madison Avenue International LP | 0 | 3,606,203 | 0 | 3,606,203 | SCHEDULE 13G, 2026-06-23 |
| Madison Avenue Partners, LP | 0 | 3,606,203 | 0 | 3,606,203 | SCHEDULE 13G, 2026-06-23 |
| EMAI Management, LLC | 0 | 3,606,203 | 0 | 3,606,203 | SCHEDULE 13G, 2026-06-23 |
| Madison Avenue GP, LLC | 0 | 3,606,203 | 0 | 3,606,203 | SCHEDULE 13G, 2026-06-23 |
| Caraway Jackson Investments LLC | 0 | 3,606,203 | 0 | 3,606,203 | SCHEDULE 13G, 2026-06-23 |
| Eli Samaha | 0 | 3,606,203 | 0 | 3,606,203 | SCHEDULE 13G, 2026-06-23 |
The latest filing identifies Lakefront Biotherapeutics NV by CUSIP 36315X101 and gives its principal executive office as SCHALIENHOEVEDREEF 20T, 2800 MECHELEN (SCHEDULE 13G, 2026-06-23).
What the percentages are based on
The following percentage is based on 65,897,071 Ordinary Shares outstanding as of December 31, 2025, as disclosed in the Issuer's Annual Report on Form 20-F, filed with the Securities and Exchange Commission on March 26, 2026. As of June 23, 2026, the Reporting Persons may be deemed to have beneficially owned approximately 5.5% of the outstanding Ordinary Shares.Madison Avenue International LP, SCHEDULE 13G, 2026-06-23
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and restated in its entirety as follows: All of the Shares reported herein were purchased by the Funds for an aggregate purchase price of $399,380,734.97 including fees and expenses, excluding fees with respect to the conversion of ADSs to Ordinary Shares. In connection with the surrender of certain ADSs held by the Funds and withdrawal of ordinary shares of the Issuer from Citibank, N.A., as depositary (the "Depositary" and such exchange, the "ADS Conversion"), the Funds paid $293,693.40 in fees to the Depositary.EcoR1 Capital, LLC, SCHEDULE 13D/A, 2025-07-28
Purpose of Transaction (Item 4)
EcoR1 Capital, LLC
No amendment to this Item is being made.Item 4 of the SCHEDULE 13D/A filed 2025-07-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-28 | EcoR1 Capital, LLC | 13.22% | SCHEDULE 13D/A |
| 2025-10-29 | Tang Capital Management, LLC | 8.4% | SCHEDULE 13G |
| 2026-06-23 | Madison Avenue International LP | 5.5% | SCHEDULE 13G |
Questions about who owns Lakefront Biotherapeutics NV
Who owns Lakefront Biotherapeutics NV?
On this page, 3 holders' latest ownership filings report 5% or more of Lakefront Biotherapeutics NV: EcoR1 Capital, LLC (13.22%, Schedule 13D/A, filed 2025-07-28), Tang Capital Management, LLC (8.4%, Schedule 13G, filed 2025-10-29) and Madison Avenue International LP (5.5%, Schedule 13G, filed 2026-06-23).
Who are the largest shareholders of Lakefront Biotherapeutics NV?
By the share each holder's latest filing reports, the largest holders of Lakefront Biotherapeutics NV on this page are EcoR1 Capital, LLC (13.22%), Tang Capital Management, LLC (8.4%) and Madison Avenue International LP (5.5%).
When did EcoR1 Capital, LLC buy into Lakefront Biotherapeutics NV?
The filings give report dates, not purchase dates. The earliest filing from EcoR1 Capital, LLC on this page is the Schedule 13D/A, filed 2025-07-28, reporting 13.22%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Lakefront Biotherapeutics NV. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.